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The	Fas/FasL	system	is	a	major	regulator	of	apop-
tosis	 [9].	Fas	 is	a	cell	 surface	protein	with	a	single	
transmembrane	domain,	belonging	to	the	nerve	growth	
factor	receptor/TNF	receptor	 family	 [15,	22].	FasL	 is	
a	type	 II	membrane	protein	 that	belongs	 to	 the	TNF	
family	[15,	22].	FasL	is	expressed	in	activated	T	cells	
and	lung	cancer	cells	[15,	19,	22].	Fas	is	expressed	on	
the	surface	of	cell	membranes	 in	a	variety	of	normal	
tissue	cells	and	malignant	cells	including	lung	cancer	
cells	[19].
Fas-mediated	apoptosis	leads	to	the	elimination	of	
activated	T-cells	following	an	immune	response.	i.	e.,	
killing	a	tumor	[1].	Deregulation	of	Fas-mediated	apop-
tosis	is	thought	to	play	a	role	in	the	cancer	progression,	
lymph	node	involvement	and	metastasis	[19].
It	 has	 been	 suggested	 that	 Fas/FasL	 systems	
induce	apoptosis	of	activated	immune	cells	and	that	
the	soluble	isoforms	of	these	proteins	(sFas,	sFasL)	
also	inhibit	their		functions	[3].	Elevated	serum	levels	
of	sFas	and	sFasL	have	been	observed	in	patients	with	
many	kinds	of	cancer	[6,	7,	21].	The	sFas	function	has	
not	yet	been	 fully	elucidated,	but	 there	are	several	
findings	suggesting	the	role	of	sFas	in	cancer	progres-
sion	[21].	sFas	has	been	reported	to	play	an	important	
role	 in	 the	 regulation	of	apoptosis	as	an	 inhibitor	of	
Fas-mediated	apoptosis	[21].	It	has	been	revealed	that	
the	Fas/FasL	system	is	an	important	mechanism	for	
tumor	escape	from	the	immune	system:	expression	of	
FasL	on	tumor	cell	surfaces	and	emission	of	a	soluble	
form	of	FasL	[15,	22].	Soluble	Fas	and	FasL	levels	are	
increased	in	peripheral	blood	of	lung	cancer	patients	
[19].	However,	the	clinical	significance	of	circulating	
sFas	and	sFasL	has	not	been	clarified,	yet.	
Materials and Methods
Patients. The	study	included	80	patients	with	car-
cinoma	of	the	lung.	They	consisted	of	69	males	and	
11	females	 (mean	age	of	64	years;	 ranged	29–78).	
The	 tumors	were	histologically	classified	as	adeno-
carcinoma	 in	8	cases,	squamous	cell	 carcinoma	 in	
40	cases	and	small	cell	carcinoma	in	32	cases.	None	
of	the	patients	suffered	from	infectious,	allergic,	auto-
immune,	or	other	systemic	diseases	such	as	diabetes	
mellitus.	The	patients	had	not	been	previously	treated	
with	chemotherapy.	The	control	group	for	serum	sFas	
and	sFasL	concentrations	comprised	15	healthy	vo-
lunteers	(12	males)	with	mean	age	of	61	years.	There	
were	no	significant	differences	in	age	and	sex	between	
patients	and	controls.	All	 patients	had	a	history	of	
smoking.	Informed	written	consent	was	obtained	from	
all	healthy	volunteers	and	all	patients.	
Methods.	Before	treatment,	patients	underwent	
standard	staging	procedures	consisting	of	physical	
examination,	 serum	chemistry	examination,	bron-
choscopy,	chest	CT	scan	and	ultrasonography	of	the	
abdomen.	 Further	 imaging	 techniques	were	used	
when	 required	clinically.	 The	clinical	 stage	of	 non	
small	cell	lung	cancer	(NSCLC)	was	assigned	accord-
ing	 to	 the	 International	Union	Against	Cancer	 (TNM	
classification).	The	classifications	of	small	cell	 lung	
cancer	(SCLC)	were	made	according	to	the	Veterans	
Administration	Lung	Cancer	Study	Group	(LD-limited	
disease;	ED-extensive	disease).	After	 staging,	 the	
patients	were	placed	on	cisplatin	or	platin-derived	che-
motherapy,	which	was	accompanied	by	radiotherapy	
in	 the	 locally	advanced	 forms.	Standard	criteria	 for	
an	objective	 response	 to	 therapy	were	used	 (WHO	
guidelines).	 To	 exclude	 the	possible	 interference	
of	chemotherapy,	 subsequent	blood	samples	were	
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obtained	at	 least	28	days	after	 the	 last	administra-
tion	of	cytotoxic	drugs.	To	determine	sFas	and	sFasL	
serum	concentrations,	 venous	blood	samples	were	
collected	from	each	patient	before	and	after	IV	cycles	
of	chemotherapy	 (some	of	 the	patients	underwent	
later	 radiotherapy).	Serum	samples	were	obtained	
by	centrifugation	and	stored	at	–80	°C	until	assayed.	
Serum	sFas	and	sFasL	concentrations	were	measured	
by	a	single	laboratory	with	an	enzyme	immunoassay	
(Human	sFas	Immunoasay	—	R	&	D	systems;	human	
sFas	Ligand	ELISA	—	Bender	MedSystems)	according	
to	the	manufacturer’s	instructions.
Statistical analysis.	 Data	were	presented	 as	
mean	±	1	SD	or	median	(range),	depending	on	their	
normal	or	skewed	distribution	provided	by	Shapiro-
Wilk’s	W-test.	Data	 for	 sFas	and	sFasL	concentra-
tions	 in	 the	 serum	samples	 from	healthy	 subjects	
and	 from	patients	with	 lung	cancer	were	analyzed	
using	Student’s	t-test	for	independent	samples.	Dif-
ferences	among	groups	of	patients	before	and	after	
chemotherapy	were	determined	using	Student’s	t-test	
for	dependent	samples.	In	the	case	of	skewed	distri-
bution,	the	data	were	analyzed	using	Wilcoxon’s-test	
and	Mann-Whitney’s	U-test	 for	unpaired	data.	The	
correlation	between	 the	parameters	was	calculated	
by	the	Spearman’s	and	Pearson’s	rank	tests.	
All	p	 values	were	 two-tailed,	and	 the	values	 less	
than	0.05	were	considered	statistically	 significant.	
Computations	were	performed	using	Statistica	6.0	for	
Windows	(StatSoft	Inc.,	Tulsa,	OK.,	USA).	
results
Serum sFas and sFasL levels in healthy volun-
teers and patients with lung cancer. As	shown	in	
Table	1,	the	serum	sFas	and	sFasL	levels	observed	at	
the	end	of	the	chemotherapy,	were	significantly	higher	
in	80	patients	with	lung	cancer,	compared	to	15	healthy	
volunteers	(p	=	0.017;	p	=	0.037).	The	levels	of	sFas	
and	sFasL	were	higher	after	chemotherapy	than	before	
chemotherapy	(p	=	0.00001;	p	=	0.023).	
The	levels	of	sFasL	were	higher	in	SCLC	patients	
than	in	NSCLC	ones.	There	were	no	significant	diffe-
rences	in	serum	sFas	with	regard	to	a	histologic	type	
(Table	1).
There	were	no	 significant	differences	 in	 serum	
sFasL	levels	in	relation	to	clinical	stage	of	NSCLC	and	
SCLC	(Table	1).		
Serum sFas and sFasL levels in relation to re-
sponse to therapy. There	were	no	significant	differ-
ences	in	serum	sFasL	levels	in	relation	to	response	to	
therapy	(Table	2).	At	the	end	of	the	therapy	the	serum	
levels	of	sFas	were	higher	 in	Partial	Response	group	
than	in	Progressed	patients	(p =	0.032)	(Fig.	1).	Before	
chemotherapy	the	levels	of	sFas	were	higher	in	Progres-
sive	Disease	group	than	in	No	Change	group	(p	=	0.02)	
(Table	2).	In	NSCLC	group,	the	levels	of	sFas	observed	
after	chemotherapy	were	higher	 in	Partial	Response	
group	than	in	No	Change	group	(p	=	0.03)	(Table	2).	
After	chemotherapy	the	levels	of	sFas	were	higher	in	
patients	with	metastases	(p	=	0.02)	(Fig.	2).
Table 1. Serum sFas and sFasL �eve�s in �ung cancer patients and contro�s
Disease 
stage
Be�ore chemotherapy 
(p-va�ue vs contro�s)
A�ter chemotherapy 
(p-va�ue vs contro�s)
Contro�s  
(n = ���)
Lung carcino-
ma patients 
(n = ��0)
sFas
sFasL
 
���.�� ± 2��* 
���7.2 (�66–��0�)# 
 
�22�.� ± �0�** 
p = 0.0�7
�02.� (���–���0)## 
p = 0.0�7
 
227.� ± �2
�26.7 (����–��70)
NSCLC  
(n = ���)
sFas
sFasL
�007.�� ± 2�6 
���.6 (�66–6��0)�
�2���.0 ± ���� 
�6�.�� (���–����)� 
III B (n = 2��)
sFas
sFasL
�66.2 ± 2���� 
�6�.�� (��7–����)
����2.7 ± �����
�72.�� (���–����) 
IV (n = 2�)
sFas
sFasL
�07��.7 ± ���� 
���.6 (�66–6��0)
�����.�� ± ��2
����.� (�66–�0�)
SCLC (n = �2)
sFas
sFasL
�6��,0 ± �06 
�67.� (26�–��0�)2
����.� ± ��� 
���2.� (�66–���0)�
LD (n = ���)
sFas
sFasL
��0.� ± �0��
�6�.7 (27��–��0�)
�2���.6 ± ��2
���2.� (2����–���0)
ED (n = �7)
sFas
sFasL
�0�0.�� ± �07
�67.� (26�–�0�)
��70.�� ± �2��
�7�.� (�66–���)
Notes: sFas – so�ub�e Fas (pg�m�); sFasL – so�ub�e Fas Ligand (pg�m�); 
* vs ** p = 0.0000� ; # vs ## p = 0.02�; � vs 2 p = 0.0�; � vs � p = 0.0�.
fig. 1. The	serum	 levels	of	sFas	after	chemotherapy	of	 lung	
cancer	in	respect	to	response	to	therapy
Table 2. Va�ues o� sFas and sFasL be�ore and a�ter chemotherapy o� �ung cancer patients
PR (n = ���) NC (n = �7 ) PD (n = �6)
be�ore chemotherapy a�ter chemotherapy be�ore chemotherapy a�ter chemotherapy be�ore chemotherapy a�ter chemotherapy
NSCLC (n = ���)
sFas
sFasL
�000.� ± 272
���.6 (2���–����)
�����.0 ± �76*
�6�.�� (2����–��7)
�0�.2 ± ���*#
���7.2 (�66–6��0)
�����.�� ± �20**
�6�.�� (���–����)
��20.�� ± 27��##
����.2 (��7–���2)
���0.� ± 2���#
�6��.6 (2�7–����)
PR (n = �7) NC (n = �) PD (n = �2)
be�ore chemotherapy a�ter chemotherapy be�ore chemotherapy a�ter chemotherapy be�ore chemotherapy a�ter chemotherapy
SCLC (n = �2)
sFas
sFasL
�0�2.6 ± 272
�7�.� (26�–��0�)
�20�.� ± ���
���2.� (�66–�����)
�����.0; ��7��.�; ����.�
��2.2; ���2.�; ���2.�
��77.�; �����.7; �2��0.2
����.��; �67.�; ���2.��
��0�.�� ± ��2
����.�� (2�2–��7)
���0.6 ± ��7
���2.� (20�–���0)
Notes: sFas — so�ub�e Fas (pg�m�); sFasL — so�ub�e Fas Ligand (pg�m�); PR — partia� response; NC — no change; PD — progressive disease vs ** p = 0.0�; 
* vs # p = 0.00��; *# vs ## p = 0.02.
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fig. 2. The	serum	 levels	of	sFas	after	chemotherapy	of	 lung	
cancer	in	Mo	and	M1	patients
discussion
Many	studies	have	revealed	that	the	Fas/FasL	sys-
tem	is	an	important	mechanism	for	tumor	escape	from	
the	immune	system:	expression	of	FasL	on	tumor	cell	
surfaces	and	release	of	a	soluble	form	of	FasL	[15,	22].	
The	high	serum	sFas	concentration	was	proved	in	pa-
tients	with	cancers:	hepatocellular	carcinoma	[6],	renal	
cell	carcinoma	[7]	and	breast	cancer	[21],	which	is	in	
accordance	with	the	results	of	our	study.	We	proved	
that	sFas	concentration	observed	after	chemotherapy	
was	higher	in	the	serum	of	patients	with	lung	cancer	
than	 in	 healthy	 individuals.	Higher	 concentrations	
were	also	observed	 in	 lung	cancer	patients	before	
chemotherapy	in	comparison	with	healthy	individuals,	
though	the	differences	were	not	statistically	significant.	
Similarly,	Yoshimura	et	al.	[23]	and	Shimizu	et	al.	[19]	
showed	higher	serum	sFas	concentrations	in	patients	
with	lung	cancer	compared	to	healthy	individuals.	
The	origin	of	sFas	 in	the	serum	remains	unclear,	
though	there	are	three	possible	theories.	sFas	may	be	
derived	from	the	tumor	itself	[18],	or	from	peripheral	
blood	lymphocytes	[8].	The	third	theory	indicates	that	
the	surrounding	stromal	tissue	may	produce	sFas	in	
response	to	the	tumor	or	immune	activation	[12].	sFas	
is	formed	due	to	cleavage	of	the	external	part	of	extra-
cellular	Fas	and	acts	as	a	FasL	inhibitor	to	bind	Fas	and	
prevent	Fas-	mediated	apoptosis.	Nonomura	et	al.	[16]	
claimed	that	immune	cells,	essentially	lymphocytes,	
NK	and	T	cells	were	 the	most	 important	sources	of	
sFas	in	response	to	a	developing	tumor.	However,	the	
results	of	our	study	suggest	that	cancerous	cells	are	
the	main	source	of	sFas	in	the	serum	of	patients	with	
lung	cancer.
The	enhanced	serum	concentration	if	an	apoptosis	
inhibitor	(sFas)	in	patients	with	lung	cancer	reflects	an	
intense	inhibition	of	cancerous	cells	apoptosis,	which	
promotes	 the	development	of	 the	 tumor.	Micheau	
et.	al.	[11]	proved	that	cytostatics	caused	the	increase	
in	serum	sFas,	whereas	Shimizu	et	al.	 [19]	showed	
that	sFas	increased	in	the	serum	together	with	clinical	
staging	of	cancer.	Our	study	confirmed	this	finding	—	
sFas	concentration	was	higher	after	chemotherapy	
than	before	treatment,	where	as	patients	with	distant	
NSCLC	metastases	had	higher	sFas	concentration	
than	patients	without	metastases.	
We	 found	 that	patients	with	NSCLC	that	showed	
partial	remission	(PR)	after	chemotherapy,	had	higher	
sFas	concentration	than	patients	with	No	Change	(NC)	
or	Partial	Response	(PR).	Cytostatics	destroying	can-
cerous	cells	may	release	sFas	from	these	cells.	
The	 results	of	 our	 study	are	 in	 agreement	with	
Kondera-Anasz’s	et	al.	study	[9]	based	on	the	group	
of	women	with	cervical	cancer,	and	with	Midis’s	et	al.	
[12]	findings	based	on	nonhematopoietic	human	ma-
lignancy.	The	high	serum	sFas	concentration	 found	
in	patients	with	metastases,	may	cause	 resistance	
to	treatment	by	inhibiting	Fas-mediated	apoptosis	in	
cancer	cells	 [21].	Various	observations	of	different	
cancers	may	 indicate	 that	 the	mechanism	of	 sFas	
induction	might	differ	depending	on	tumor	type.
We	 did	 not	 prove	 that	 determination	 of	 sFas	
concentration	might	be	useful	in	diagnostics	of	lung	
cancer	Shimizu	et	al.	[19]	indicated	such	a	possibility,	
however,	it	requires	further	studies	performed	in	more	
numerous	groups	of	patients.	
In	addition	to	Fas,	FasL	also	exists	in	a	soluble	form	
released	from	cell	surfaces	after	cleavage	by	metal-
loproteinases	[20].	FasL	 is	expressed	 in	activated	T	
cells	and	lung	cancer	cells	[2].	An	increase	in	serum	
sFasL	concentration	was	proved	in	patients	with	vari-
ous	cancers	[4,	17].	It	has	been	proposed	that	cancer	
cells	expressing	FasL	have	an	advantage	 to	evade	
human	 immune	surveillance	by	 inducing	apoptosis	
in	infiltrating	lymphocytes	expressing	Fas	[1].	sFasL,	
cleft	by	metalloproteinases,	protects	FasL	of	 tumor	
cells	against	their	recognition	by	Fas	of	T	lymphocytes	
(imitation	of	 tumor	cells).	Shimuzu	et	al.	 [19]	 sug-
gested	that	soluble	FasL	played	an	important	role	in	
tumor	genesis	and	anticancer	cytotoxic	activity,	similar	
to	soluble	Fas.	
The	behavior	of	serum	sFasL	in	cancer	patients	is	
controversial.	Enjoji	et	al.	[3]	showed	that	the	levels	
of	sFasL	were	not	detectable	in	biliary	carcinoma	pa-
tients.	InMurakami’s et al. [14] study, the serum levels	 	 	 	 	 	 	 	 	
of	sFasL	were	significantly	lower	in	bile	duct	carcinoma	
patients	than	in	healthy	individuals.	Conversely,	Ichi-
kura	et	al.	 [5]	showed	 that	 the	 levels	of	sFasL	were	
higher	 in	gastric	carcinoma	patients	 than	 in	healthy	
volunteers.	Our	results	are	in	agreement	with	obser-
vations	made	by	 Ichikura	et	al.	 [5].	We	showed	that	
the	levels	of	sFasL	in	lung	cancer	patients	(observed	
after	chemotherapy)	were	higher	than	in	controls.	The	
same	observations	were	made	by	Mouawad	et	al.	[13]	
in	melanoma	patients.	In	this	study,	the	levels	of	sFas	
and	sFasL	in	patients	were	higher	in	patients	than	in	
healthy	donors.	We	did	not	observed	significant	diffe-
rences	in	serum	sFasL	level	in	relation	to	clinical	stage	
of	the	tumor.	The	same	observations	were	made	by	
Melzani	et	al.	[10]	in	patients	with	melanoma.
When	SCLC	is	diagnosed,	cancer	cells	are	already	
present	in	the	whole	organism,	transported	via	blood	
vessels	(independently	of	classification	by	imagining	
tests	as	ED	or	LD).	Thus,	it	is	justified	that	we	found	
the	higher	sFasL	concentration	in	patients	with	SCLC	
than	NSCLC.	
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Summing	up,	sFas	and	sFasL	play	a	significant	role	
in	patients	with	lung	cancer.	Determination	of	serum	
sFas	and	sFasL	concentrations	may	be	helpful	to	as-
sess	clinical	 staging	and	effects	of	chemotherapy.	
However,	it	requires	further	studies.	
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Уровень� sfas �� sfasl в ��воро��е �ров�� �о�ь�н���    
ра�ом� �е��о�о на �оне ����м���о�ера�����     
Цель� работы� �� о����т�� ������������ �����ообра��о�т�� о�р��������� �ро���� ра�т�ор��о�о Fas (sFas) � ра�т�ор��о�о            
���а��а Fas (sFasL) � �ы��орот�� �ро�� бо����ы��� ра�о� ����о�о �р� �����от�ра���.           Методы: об����о�а�� 80 �а����то� 
(69 ��ж��� � 11 ж��щ��; �р����й �о�ра�т �� 64 �о�а; �� ���� � 48 ��а��о�т�ро�а� ������о���то��ы�й ра� ����о�о (НМКРЛ), 
� 32 �� ����о���то��ы�й ра� ����о�о (МКРЛ)). Ко�тро����а�� �р���а �о�то���а �� 15 ��оро�ы��� �о�оро�. Обра��ы� ��р�ф�-
р�����ой �ро�� бра�� �о � �о��� 4 ��р�о� �����от�ра���. Со��ржа��� sFas � sFasL а�а����ро�а�� �����оф�р���т�ы��     
��то�о�. Резуль�таты: �ро��� sFas � sFasL � �ы��орот�� �ро�� ����� бо����ы��� ра�о� ����о�о �о о�о��а��� �����от�ра���             
�ы�ш�, ��� та�о�ы�� � �о�тро����ой �р���� � ��� та�о�ы�� �о т�ра���. Уро����� sFasL бы�� ��а��т�����о �ы�ш� � бо����ы���      
МКРЛ, ��� та�о�ой � �а����то� � НМКРЛ. З�а��т�����ы��� ра�����й � �ро��� sFasL � �ы��орот�� �ро�� � �а�����о�т� от       
���������ой �та��� �або���а���� �� �ы�������о. По о�о��а��� �����от�ра��� �ро����� sFas �ы�ш� � �а����то� � ��та�та�а��,      
а та�ж� � �р���� � �а�т���ы�� от��то� �а т�ра����, ��� � бо����ы��� � �ро�р����р���щ�� �або���а����. До �а�а�а т�ра��� 
�ро����� sFas бы�� �ы�ш� � бо����ы��� � �ро�р����р���щ�� �або���а����, ��� � �а����то� �о �таб�����ы�� �о�то������, а �о                
о�о��а��� т�ра��� – � бо����ы��� � �а�т���ы�� от��то� �о �ра������� � �р���ой бо����ы��� �о �таб�����ы�� �о�то������. Выводы: 
о�р�������� �ро���� sFas � sFasL � �ы��орот�� �ро�� �ож�т бы�т�� �р������о � ���������ой �ра�т���, �о ��а���о�т�� та����               
�о�а�ат���й ��об��о���о о�р�����т�� � �а�����йш��� ������о�а������. 
Ключевые слова: ра�т�ор��ы�й Fas, ра�т�ор��ы�й ���а�� Fas, ����о���то��ы�й ра� ����о�о, ������о���то��ы�й ра� ����о�о,          
�����от�ра����.
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